Strategic leadership Recent C-suite changes with a new CEO (David Liese) signal potential shifts in strategic priorities and willingness to pursue growth partnerships in biocatalysis and cell-free manufacturing. Use this timing to propose expanded collaboration, co-development, or pilot projects aligned with greener production.

Scale-up capabilities Strong positioning as a partner from gram to ton-scale in industrial biocatalysis and cell-free manufacturing presents opportunities to convert early-stage enzyme discoveries into full-scale production, including process optimization services and technology transfer for clients seeking greener, safer manufacturing.

Partnership potential Existing collaboration with Solvias indicates openness to strategic partnerships for chemocatalysis and biocatalysis platforms. Leverage this to present joint development programs, access to complementary analytical and development capabilities, and expanded service scope.

Broad capabilities Capabilities spanning enzymology, cloning and expression in multiple hosts, and strain and fermentation development for therapeutic/diagnostic protein manufacture enable cross-domain selling to biotech and pharma clients seeking end-to-end enzyme and process solutions.

Smaller footprint, agility Small team size (2-10 employees) but nearly 15 years in the field suggests a boutique, high-touch service model with potential for scalable, specialized projects, making it suitable for targeted outreach to mid-market biotech firms seeking customized, rapid-value engagements.